Uncy stock forecast 2025 consensus EPS revisions for "uncy

Consensus EPS revisions for "uncy stock forecast 2025" have trended upward for three consecutive months, suggesting analyst confidence in profitability growth. Taysha’s lead asset is TSHA-102, a self-complementary intrathecally delivered AAV9 gene transfer therapy specific to Rett. The drug therapy is designed for one-time dosing, to deliver a corrected copy of the MECP2 gene to central nervous system cells, thereby addressing the genetic root cause of the disease condition. The drug candidate is currently undergoing two Phase 1/2 clinical trials, the REVEAL adolescent and adult study, in the US and Canada, and the REVEAL pediatric study in the US and the UK. Early data from both studies, based on two patients, showed a well-tolerated safety profile for the drug candidate, and an absence of adverse effects linked to the therapy. Based on these results, the company plans to advance the trials to a second cohort at a higher dose. Be the first to see our newest insights and key updates across all datasets The dividend policy remains unchanged, but "uncy stock forecast 2025" could initiate payouts if free cash flow exceeds projected thresholds, enhancing appeal to income-focused portfolios.